

## Index

### **a**

- acetonitrile 29–32, 35, 44, 64, 65, 74, 78, 93, 97, 107, 110, 116, 118, 121, 125, 133, 174, 203, 226, 228, 229, 234, 236, 258, 259, 263, 269, 270, 276, 278, 281, 282, 285, 287, 291–295, 297, 298, 300, 301, 306, 319, 345, 346, 347, 369, 372, 379, 381
- acetyl pyridine 147, 148
- achiral separations 90–93
- acidic functional groups 152–153, 255
- acidic pH values 31, 43
- acidity constants
  - acid constant estimation 263
  - influence on peak shape 259–263
  - polarity of acidic or alkaline substances 257–259
  - UV spectra 259
- active pharmaceutical ingredients (API) 108, 255, 278–279
- additives 43–44, 52, 54, 65, 76, 81, 83, 87–90, 93, 96–97, 100, 101, 114, 117–119, 123–126, 135, 151, 182, 184, 190, 236, 292, 294, 319, 320, 363, 368, 370, 372
- advanced thermal equilibration control (ATEC) 356
- Agilent 1100 HPLC system 321
- Agilent 1290 Infinity II Flexible Pump 319
- Agilent InfinityLab Quick Connect UHPLC Column Fittings 314
- Agilent technologies
  - automation 319–321
  - HDR 325–326
  - ISET 326–327
  - laboratories sample throughput
    - alternating column regeneration 316
    - dual needle multisampler 316
    - StreamSelect 316–317
  - modular or stepwise upgrade of existing systems 318
  - multimethod and method development systems 321–322
  - multiwash 317–318
  - online SPE 322–323
  - second chromatographic dimension (2D-LC) 323–324
  - separation performance
    - minimizing the dispersion 314–315
    - zero dead-volume fittings 314
  - SFC-HPLC hybrid system 324–325
- Agilent 1290 Infinity II High Dynamic Range Diode Array Detection (HDR-DAD) Impurity Analyzer Solution 325
- alcohols 121
- aldehydes, hydrate formation of 146–148
- amylose derivatives 131
- analytical procedure lifecycle management (APLM) approach 199, 201
- analytical quality-by-design (AQbD) advantage 375, 377
- Fusion QbD 377

- analytical target profile (ATP) 201–202, 217
  - antibody–drug conjugates (ADCs) 59, 76
  - APLM Stage 1 202–204
  - APLM Stage 2 199, 202, 214
  - assistant AZURA ASM 2.2L 333
  - automated method development 49, 180–182, 184–188, 196, 243, 368–374
  - automated method scouting (AMS) 368, 370–372
  - automatic optimization 180, 181
- b**
- best overall answer (BOA) 378, 381
  - Bioinert components 340
  - BlendAssist 320
  - budesonide 376, 378, 379, 381
  - building block phase 245, 248
  - butamiride dihydrogen citrate, cough syrup 279, 283, 284
- c**
- carbonyl compounds 147, 271
  - cation exchange chromatography (CEX) 74
  - computer-assisted method development (CAMD) 180
  - charged aerosol detection (CAD) 291, 357, 361
  - chemical and enzymatic modifications 57
  - chemical oxidation 44
  - chemistry system screening 202, 204–207, 377
  - chiral chromatography 133
  - chiral HPLC and SFC 110, 132–135
  - chiral polysaccharide stationary phases 110–113
  - chiral separation 88–90, 93, 96, 100, 101, 107–138, 180
  - chiral stationary phase (CSP) 88, 96, 107
  - chromatographer 89, 98, 147, 163, 180, 194
  - chromatographic modes 58, 64, 66, 74, 76, 102, 201
  - chromatographic optimization parameters 97
  - chromatographic separation
    - conjugated ADC 76
    - mobile phase modifiers 76
    - monoclonal antibody 74
    - protein formulations 74
    - released and labeled *N*-glycans 74
    - size exclusion chromatography 76
  - chromatography data system (CDS) 49, 180, 182, 191, 192, 362, 364
  - Chromeleon eWorkflows 370
  - ChromSwordAuto® 180–182, 184, 332, 370, 372, 373
  - coated CSPs 113
  - coefficient of variation (VC) 165, 166, 171–175
  - coinjection 346–348
  - column bleeding 35, 49, 51
  - column identification kits 327
  - column selection 89, 321, 334, 370
  - conjugated antibody–drug conjugates (ADCs) 59, 76
  - cosmotropic salinity 33
  - critical quality attributes (CQA) 189, 192, 357, 368
  - cumulative desirability result 378
  - CUP laboratories 239–249
  - cyproconazole 119
- d**
- data integrity 200, 216
  - design of experiments (DOE) 87, 96, 99, 102, 180, 201, 217, 377, 378
  - difluoroacetic acid (DFA) 66
  - dimethyl formamide (DMF) 148, 149, 256
  - diode array (DAD) 87, 171, 272, 325, 357, 361
  - 1,4-dioxane 149
  - distance effects 152
  - donor–acceptor interactions 142, 146

- drug development
  - early stages of 185
  - late stages of 185
- dual LC mode for operation 357, 369
- e**
- electrospray ionization (ESI) 39, 40, 79, 100, 287
- Empower Validation Manager 383
- enantiomer separation problems 135–136
- enantioselective chromatography 108, 137
- E-phase, or Execute 245
- Erlenmeyer rule 147
- ethers, peroxide formation of 150, 151
- ethyl acetate 113, 121, 125, 149, 255, 291, 345
- 2-ethylpyridine-bonded silica stationary phase 90
- f**
- fast chiral separations 136–138
- fit for purpose method 109
- flow injection analysis (FIA) 44
- fluorescence detection (FLD) 74, 78, 304, 357
- formoterol 376–379, 381
- functional moieties, impact of 142–143
- Fusion QbD 377
  - BOA 378, 381
  - DOE approach 377, 378
  - S-Matrix 383
- g**
- generic methods
  - active pharmaceutical ingredients 278–280
  - butamirate dihydrogen citrate, cough syrup 279
  - highly polar compounds 282
  - limits of 279
  - MS detection improvement 282
  - proteins 282
  - strongly nonpolar connections 282
  - UV detection, deep wavelength range 282
- gradient delay volume (GDV) adjustment 356, 359–361
- gradient methods 95, 96, 167, 184, 185, 269, 283, 295, 372, 382, 383
- gradient separations 42, 74, 78, 167, 168, 358
- h**
- Hansen-solubility parameters 160, 162
- High-Definition Range (HDR) HPLC 325
- high-efficiency stationary phases 92
- high performance chromatography 58
- high performance liquid chromatography (HPLC)
  - acid–base constants 255
  - Agilent technologies 313
  - avoidance of peak tailing 295–302
  - basic functional groups 153–155
  - blank samples 287–288
  - column dimension and particle sizes 305–308
  - content method 242
  - dissolved analytes, stability of 255, 272–278
  - experimental data 226
  - intelligent and self-contained 362
  - measurement uncertainty and method design
    - calibration–calibration model 304–305
    - detection 304
    - dilutions 303
    - internal standards 305
    - peak shape/separation 304
    - weighing in or measuring 302–303
  - multidimensional separation modes 80
  - nonpolar analytes 228
  - octanol–water partition coefficient 254, 255, 263–270
  - optimizing sensitivity 79–80
  - pH value in 151–152

- high performance liquid chromatography (HPLC) (*contd.*)
    - polar analytes 228–230
    - process control analytics 235–237
    - quality control 234–235
    - research and development 221, 233–234
    - robust approaches 222
    - software assisted automated method development 368–374
    - solubility 252–257
    - speed optimization 77–79
    - task, definition of 252
    - 2D-LC separations 363–368
    - UNTIE® process, CUP laboratories 239
    - UV absorption 255, 270–272
    - UV detection wavelengths 288–291
    - Vanquish Core 356–361
    - Vanquish Flex 357
    - Vanquish Horizon 357
  - high pH reversed-phase (RP)
    - fractionation 81
  - high-pressure proportioning gradient pump (HPG) 357
  - high-resolution accurate mass
    - spectrometers (HRAMS) 47, 356
  - high-resolution/accurate mass (HR/AM)
    - measurements 47, 356
  - host-cell protein (HCP) contaminants 81
  - hybrid modes 7–8
  - hydrogen bonds 26, 27, 91, 94, 134, 142–146, 148, 150, 154, 156, 158–161, 224
  - hydroperoxides 150, 151, 156, 157
  - hydrophilic interaction liquid chromatography (HILIC) 78
    - classification 27
    - free silica phase 26
    - 4-hydroxybenzoic acid 25
    - logD value 23
    - mass spectrometric detection 35
    - neutral stationary phases 27
    - organic solvent 28–31
    - pH value 33–34
    - salts 31–33
    - silica particles 26
    - zwitterionic stationary HILIC phases 28
  - hydrophobic compounds 76, 91
  - 1-hydroxy- and 4-hydroxybenzoic acid 23–25, 31, 32, 34
  - hydroxychloroquine (HCQ) 121
  - hyphenated method 48–49
- i**
- immobilized polysaccharide CSPs 89, 112–127
  - InfinityLab LC Companion 327
  - intelligent peak deconvolution analysis (I-PDeA) 351–353
  - intelligent run control (IRC) 370
  - Intelligent System Emulation Technology (ISET) 326–327
  - interactive forces 141, 142
  - Internet of Things (IoT) 341, 353, 354, 362
  - ion chromatography 23, 24, 240, 338
  - ion source parameters 45
  - isocratic methods 96, 170, 382
  - isocratic separations 168, 294, 361
- k**
- ketones, hydrate formation of 146–148
- l**
- L-ABGA 123
  - laboratory information management system (LIMS) 341
  - limit of quantification (LOQ) 108, 165
  - lincomycin 154, 155
  - liquid chromatography (LC) 39, 57, 200, 375
  - long life and/or easy maintenance pump heads 327
  - loop-based multi-heart-cut 2D-LC 364–366
  - loop-based single-heart-cut 2D-LC 364, 365
  - low-pressure proportioning gradient pump (LPG) 357

- low wavelengths  
 acids and buffer additives 292–294  
 drift at solvent gradients 294–295  
 solvents 291–292
- m**
- macrocyclic glycopeptide CSPs 89  
 MarvinSketch 263, 270  
 mass accuracy 47  
 mass spectrometry (MS) 3, 7, 12, 14, 15,  
 23–36, 39, 40, 42, 43, 50–54, 58, 76,  
 81, 87, 100, 137, 200, 234, 272, 352,  
 359, 378  
 control software 48  
 detection 12–14, 41–43, 47–49, 52, 73,  
 79, 81–83, 282, 301, 364, 367, 369,  
 382  
 methanol 29, 30, 44, 93–95, 97, 101, 110,  
 113, 116, 118, 121, 125, 133, 135,  
 148, 153, 167, 226, 227, 254–256,  
 270, 274, 278, 281, 287, 291–294,  
 301, 319, 325, 345, 348, 369, 372  
 method development (MD) 3–18, 28, 29,  
 39–54, 88, 96, 101, 102, 109,  
 179–182, 184–188, 192, 194, 196,  
 199–217, 221–231, 235, 236, 239,  
 241–245, 248, 249, 252, 253, 272,  
 318, 320–322, 337, 350, 351, 359,  
 367–383  
 method operable design region (MODR)  
 199, 208, 213, 217, 375  
 method scouting 243–245, 322, 368,  
 370–373  
 mobile-phase composition (MP) 13, 87,  
 90, 93, 95–99, 101, 213, 368  
 mobile-phase modifiers 76, 127  
 mobile phase production  
 buffer solutions preparation of 285  
 degassing 287  
 filtration of solvents and buffer  
 285–287  
 reagents 283–285  
 solvent measurement 284–285  
 vessels and fluid bottles 284  
 mobile-phase viscosity 78, 94
- monoclonal antibodies (mAbs) 57, 74,  
 78, 81, 82, 179–196, 200, 358  
 monovalent ions 52  
 Monte Carlo simulation 210–213  
 Monte Carlo optimization procedure  
 186  
 multidimensional separation modes  
 80–81  
 multivariate curve resolution-alternating  
 least squares (MCR-ALS) 351
- n**
- neutral stationary phases 27  
 Nexera system 243, 342, 349  
 noise reduction 171  
 normal-phase (NP) separation 9, 109,  
 113, 325
- o**
- octanol–water partition coefficient 142,  
 157–160, 162, 254, 255, 263–270  
 one factor at a time (OFAT) 99, 375  
 1D method 11, 12  
 Online SPE 318, 322–323  
 optimization, HPLC  
 assistant AZURA ASM 2.2L 333  
 automatic method optimization and  
 column screening 334–335  
 Bioinert components 340  
 catalogue of measures 331  
 chemical resistance of wetted  
 components 338–340  
 device level 332–333  
 equipment level 330  
 fractionation 335–336  
 individual optimizations, assistant  
 334  
 Internet of Things (IoT) 341  
 material certification 340  
 method levels 330  
 outcomes and improvements 329  
 peak recycling 335–336  
 personnel level 331–332  
 purification 336–337  
 sample preparation 335–336

- optimization, HPLC (*contd.*)
    - software 340–341
    - specification sheet 329–331
    - time-consuming method optimization 332
    - wetted vs. dry components 337–338
  - optimizing mean performance 207–210
  - organic solvents 4, 9, 14, 15, 25, 28–31, 33, 36, 43, 65, 74, 76, 81, 82, 112, 116, 118, 125, 136, 191, 229, 243, 255, 256, 263, 274, 276, 281, 282, 287, 302, 338, 345, 346, 372
  - out-of-specification (OOS) 202
- p**
- paracetamol 137, 160–162
  - particle size 12, 40–42, 59, 73, 75, 78, 79, 82, 83, 88, 92, 98, 99, 109, 123, 136, 166, 204, 280, 305–308, 323, 356, 361, 382
  - peak recycling 335–336
  - peak-to-noise ratio 165, 171, 172
  - PeakTracker 208
  - pharmacopoeia methods 165, 166
  - pH dependency 151, 152
  - photodiode array (PDA) detector 343, 348–349, 351
  - pH value 23, 25, 28, 31, 33–34, 36, 43, 46, 52, 142, 151–152, 155, 156, 167, 221, 257, 258, 260, 261, 263, 272, 273, 283, 285, 298, 301, 338, 377, 379
  - Pirok compatibility table 9
  - polar organic mode 110, 113–116, 124
  - polarity tables 141
  - polynuclear nitrogenous aromatics 256
  - polysaccharide-based stationary phases 88
  - polysaccharide CSPs 88, 110, 127, 129, 133, 135
  - POPLC 222, 223
  - protein biopharmaceuticals
    - high performance chromatography 58–62
    - microheterogeneity 57
    - multidimensional LC approaches 64–66
    - nondenaturing LC modes 62–64
    - therapeutic proteins and chromatographic methods 58
  - protein oxidation 183
  - proven acceptable range (PAR) 381
  - pumping system 87, 100
- q**
- quality-by-design concepts 49
  - quantitative structure–retention relationship (QSRR) modeling 372, 374
  - quaternary pumps 203, 204, 319, 320, 323
- r**
- rac-Norketotifen 107, 108
  - recombinant monoclonal antibodies (mAbs) 179
  - replication strategy 199, 202, 214, 217
  - reversed-phase HPLC methods
    - automated method development 184–185
    - columns screening 185–186
    - fine optimization and sample profiling 188
    - interaction with instruments 181–182
    - performance improvement 194, 196
    - rapid optimization mode 186–188
    - robustness test 188–189
    - sample preparation and HPLC analysis 183–184
    - software tools 180, 181
    - variables selection 189–190
  - reversed phase liquid chromatography (RPLC) 23, 24, 57, 74, 98
  - rule of thumb 80, 82, 96, 222, 252, 278, 325
- s**
- sample diluents 74, 97
  - sample injector 87

- screening coated and immobilized polysaccharide CSPs
  - in normal phase and polar organic mode 113–116
  - polar organic supercritical fluid chromatography conditions 121–125
  - in reversed-phase mode 116–119
- screening immobilized polysaccharide CSPs
  - in medium-polarity mode 119–122
  - in medium-polarity supercritical fluid chromatography conditions 125–127
- second chromatographic dimension (2D-LC) 323–324
- selective comprehensive mode (sLCxLC) 363
- semipolar phases 26, 27
- separation, HPLC
  - hyphenated method 48–49
  - ion source conditions 44–47
  - mass spectrometry 50–51
  - MS-compatible mobile phase 43
  - MS detection 47–48
  - rapid screening separations 42
  - sample throughput and separation quality 42
  - sensitivity and limit of detection 40–41
  - software-based parameter variation 49–50
- SFC–HPLC hybrid system 325
- Shimadzu LabSolutions Chromatography Software (CDS) 347
- Shimadzu Nexera Method Scouting System 245
- Shimadzu Scouting System 246
- simulated moving bed (SMB) chromatography 336, 337
- single-/multi-heartcut system 52–54
- size exclusion chromatography (SEC) 57, 76, 81, 82
- slit width 343, 348–349
- SmartInject technology 356
- SmartStroke 356
- S-Matrix Fusion QbD® Software 199, 383
  - application to chromatographic separation modes 200
  - non-LC method development procedures 200–201
  - small and large molecule applications 200
  - analytical target profile 201–202
  - APLM Stage 1 202–204
  - APLM Stage 2 214–215
  - chemistry system screening 204–207
  - experimental design and data modeling 201
  - Monte Carlo simulation 210–213
  - optimizing mean performance 207–210
  - USP <1210> 214–216
- software-assisted automated method development 368–374
- software optimization 332, 340–341
- solid phase extraction (SPE) 79
- speed optimization 77–79
- Stage-Gate® model 241
- stationary phase-optimized-selectivity (SOS) 92
- stationary phases (SP) 9, 25–34, 36, 44, 51, 52, 59, 61, 64, 66, 75, 76, 87–93, 95–98, 100–102, 107, 109–113, 124, 127, 129, 132, 135, 136, 138, 141, 151, 157, 166, 167, 204–208, 221, 222, 224, 226, 228, 234–236, 255, 257, 263, 269, 278, 280, 282, 284, 295, 297, 298, 301, 302, 305, 324, 347, 356, 364, 368, 376–378, 383
- statistical process control (SPC) 211
- statistical test planning 49
- StreamSelect 316
- streptomycin 155, 156, 159
- supercritical fluid chromatography (SFC) mobile phases 93
  - optimization parameter 97
  - polysaccharide-based stationary phases 88
  - proportion of cosolvent 94

- supercritical fluid chromatography (SFC)  
 (*contd.*)  
   SFC-MS coupling 100-101  
   synthetic polymer CSP 89  
   two-dimensional chromatography 102  
 synthetic polymer CSP 89
- t**
- target measurement uncertainty (TMU)  
   202  
 Tefzel® 338, 339  
 Thermo Scientific Vanquish Core systems  
   362  
 time-consuming method optimization  
   332, 352  
 tolerance interval (TI) 199, 202, 214-217  
 toluene 23, 24, 111, 161, 162, 256  
 trap-based single heart-cut 2D-LC for  
   eluent strength reduction  
   366-367  
 trap-based single heart-cut 2D LC-MS  
   using Vanquish Dual Split Sampler  
   367-368  
 trifluoroacetic acid (TFA) 43, 61, 76,  
   153, 186, 281, 282, 284, 285,  
   293-295, 297, 298, 301, 356, 379  
 two-dimensional liquid chromatography  
   (2D-LC) 13, 363  
   loop-based multi-heart-cut 2D-LC  
     364-366  
   loop-based single-heart-cut 2D-LC  
     364  
   trap-based single heart-cut 2D-LC for  
     eluent strength reduction  
     366-367  
   trap-based single heart-cut 2DLC-MS  
     using Vanquish Dual Split Sampler  
     367-368  
 two-dimensional separation 80  
   choice of mode 5  
   complex samples 4  
   comprehensive 2D-LC methods 13  
   difficult-to-separate samples 3  
   fixed first dimension conditions 11-13  
   four 2D separation modes 5-7  
   hybrid modes 7-8  
   LC-LC method 14  
   rules of thumb 13-14  
   separation goals 4  
   separation types/mechanisms 8-11  
   2D-LC separation of surfactants 14-17
- u**
- (U)HPLC performance  
   advanced peak processing 350-353  
   auto-diagnostics and auto-recovery  
     349-350  
   compressibility settings 345  
   mixture of water and organic solvent  
     345, 346  
   pressure and pressure fluctuations  
     343  
   single solvent 345  
 Internet of Things 353  
 photodiode array detector, silt width  
   348-349  
 solvent composition and injection  
   volume 346-348  
 systems 168  
 ultra-high-performance supercritical fluid  
   chromatography (UHPSFC) 92  
 Ultra Low Dispersion Kit 314  
 unique dual gradient pump (DGP) 357  
 United States Pharmacopoeia 241  
 UNTIE® process, CUP laboratories 248  
   development and optimization method  
     243-245  
   existing method, test of 242-243  
   understanding customer needs  
     241-242  
   validation 245-248  
 UNTIE pyramid 240  
 USP <1210> 199, 214-216  
 UV cut-off 291, 301  
 UV or diode-array detection 87
- v**
- Vanquish Core 356-362  
 Vanquish Duo-based Dual LC concept  
   358



Vanquish Flex 356–361  
Vanquish Horizon 356–361  
Vanquish (U)HPLC platform 355, 356,  
370, 372  
Vanquish Solvent Monitor (VSM)  
362  
Vanquish User Interface (VUI) 362

variable-wavelength light absorbance  
detection (VWD) 357  
volatile ionic detergents 44

**Z**

zero dead-volume fittings 314  
zwitterionic stationary HILIC phases 28









